Page last updated: 2024-10-30

metformin and Kidney, Polycystic

metformin has been researched along with Kidney, Polycystic in 4 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks."7.11Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022)
"Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys."5.91Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023)
"Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks."3.11Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022)
"Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys."1.91Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's3 (75.00)2.80

Authors

AuthorsStudies
Chang, MY1
Tsai, CY1
Chou, LF1
Hsu, SH1
Yang, HY1
Hung, CC1
Tian, YC1
Ong, ACM1
Yang, CW1
Oto, OA1
Atwood, DJ1
Chaudhary, A1
He, Z1
Li, AS1
Wempe, MF1
Edelstein, CL1
Leonhard, WN1
Song, X1
Kanhai, AA1
Iliuta, IA1
Bozovic, A1
Steinberg, GR1
Peters, DJM1
Pei, Y1
Wang, J1
Chin, D1
Poon, C1
Mancino, V1
Pham, J1
Li, H1
Ho, PY1
Hallows, KR1
Chung, EJ1

Trials

1 trial available for metformin and Kidney, Polycystic

ArticleYear
Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
    Human molecular genetics, 2022, 05-19, Volume: 31, Issue:10

    Topics: Animals; Cysts; Disease Models, Animal; Female; Kidney; Lactic Acid; Male; Metformin; Mice; Mice, Tr

2022

Other Studies

3 other studies available for metformin and Kidney, Polycystic

ArticleYear
Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease.
    Physiological reports, 2023, Volume: 11, Issue:17

    Topics: AMP-Activated Protein Kinases; Animals; Cysts; Humans; Lactates; Male; Metformin; Polycystic Kidney

2023
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
    EBioMedicine, 2019, Volume: 47

    Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cyclic AMP;

2019
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease.
    Journal of controlled release : official journal of the Controlled Release Society, 2021, 01-10, Volume: 329

    Topics: Administration, Oral; Animals; Chitosan; Drug Carriers; Drug Delivery Systems; Humans; Metformin; Mi

2021